Nouvelle déclaration d'incident
No de la demande: 2016-4213
Numéro de référence du titulaire d'homologation: 2016KP117
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer Inc
Adresse: 2920 matheson BLVD
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: k9 advantix II Unknown
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Autre
Dog / Chien
Yorkshire Terrier
1
Femme
9
Inconnu
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
Unknown / Inconnu
Système
Unknown / Inconnu
Oui
Oui
8
Day(s) / Jour(s)
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On an unspecified date in Oct 2015, the dog was lethargic. On unspecified dates in Oct 2015, Nov 2015, Dec 2015, Jan 2016 and Feb 2016, the product was reapplied. On an unspecified date post application, in Feb 2016, the dog was vomiting and not eating. On an unspecified date in Mar-2016 the product was reapplied. On an unspecified date post application, in Mar-2016, the dog was examined by a veterinarian and had a positive Lyme test. It is unknown what treatments were performed. On an unspecified date in Apr-2016 the product was reapplied. On 15-Apr-2016, the dog was referred to a veterinary teaching hospital and started on unspecified types of treatment. On 23-Apr-2016 the dog died. No known necropsy was performed. No further information is expected. Case is closed. Note: The intent of the call was to discuss product use on new pet and not to report the death of this dog.
Mort
Reported lethargy, vomiting and not eating are unspecific signs and may have numerous other causes in dog. Moreover signs likely linked to later diagnosed Lyme disease. Death reported after latest application, which is not expected as inconsistent with pharmaco-toxicological product profile, might be linked to diagnosed lyme disease or other causes more probable in an elderly dog, though no serious signs were reported to explain death. Moreover product was reapplied between the two applications followed by signs without any adverse events. Actually, the intent of the call was to discuss product use on new pet and not to report the death of this dog. Overall, though time to onset for signs are not provided and necropsy not available, considering Lyme diagnosis likely explain early signs, many applications were not followed by signs and death occurred long time after last application (over 8 days), a product connection is deemed to be unlikely.